NO872770L - Acyl. - Google Patents
Acyl.Info
- Publication number
- NO872770L NO872770L NO872770A NO872770A NO872770L NO 872770 L NO872770 L NO 872770L NO 872770 A NO872770 A NO 872770A NO 872770 A NO872770 A NO 872770A NO 872770 L NO872770 L NO 872770L
- Authority
- NO
- Norway
- Prior art keywords
- represents hydrogen
- halogen
- group
- lower alkyl
- salts
- Prior art date
Links
- 125000002252 acyl group Chemical group 0.000 title abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 229930186147 Cephalosporin Natural products 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229940124587 cephalosporin Drugs 0.000 abstract 1
- 150000001780 cephalosporins Chemical class 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Cephalosporin derivatives of the formula <IMAGE> in which m represents 0, 1 or 2, R<1> represents hydrogen or an acyl group, R<2> represents hydrogen, lower alkoxy, amino, lower alkylthio or lower alkanoylamino, R<3><1> represents hydrogen, lower alkyl, lower alkenyl, C3-C7-cycloalkyl, halogen-lower alkyl or halophenyl; Z represents R<3><0>-C or nitrogen, R<3><0> represents hydrogen or halogen, or R<3><0> and R<3><1> together represent a C3-C5-alkylene group, a C2-C4-alkylene- monooxy group or a C1-C2-alkylenedioxy group, R<3><2> represents hydrogen, halogen, lower alkyl or an optionally substituted 5- or 6-membered heterocyclic ring having one, two or three oxygen, nitrogen and/or sulphur atoms and R<3><3> represents hydrogen or halogen or R<3><2> and R<3><3> together represent a C1-C4-alkylenedioxy group, and easily hydrolysable esters and salts of these compounds and hydrates of the compounds of the formula I or of their esters and salts are described. The products have antimicrobial activity.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88155586A | 1986-07-03 | 1986-07-03 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO872770D0 NO872770D0 (en) | 1987-07-02 |
| NO872770L true NO872770L (en) | 1988-01-04 |
| NO168890B NO168890B (en) | 1992-01-06 |
| NO168890C NO168890C (en) | 1992-04-15 |
Family
ID=25378717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO872770A NO168890C (en) | 1986-07-03 | 1987-07-02 | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ACYLCEPHALOSPORINE DERIVATIVES |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0251330B1 (en) |
| JP (1) | JPH0730083B2 (en) |
| KR (1) | KR880001675A (en) |
| CN (1) | CN1021226C (en) |
| AT (2) | ATE97901T1 (en) |
| AU (1) | AU603364B2 (en) |
| CS (2) | CS270227B2 (en) |
| DE (1) | DE3788306D1 (en) |
| DK (1) | DK340387A (en) |
| ES (1) | ES2060583T3 (en) |
| FI (1) | FI88392C (en) |
| HU (1) | HU200185B (en) |
| IE (1) | IE61434B1 (en) |
| IL (1) | IL83046A (en) |
| MC (1) | MC1833A1 (en) |
| MX (1) | MX7189A (en) |
| NO (1) | NO168890C (en) |
| NZ (1) | NZ220914A (en) |
| PH (1) | PH23940A (en) |
| PT (1) | PT85246B (en) |
| ZA (1) | ZA874696B (en) |
| ZW (1) | ZW12787A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ227470A (en) * | 1987-12-28 | 1991-06-25 | Hoffmann La Roche | Acyl derivatives of substituted cephem compounds; pharmaceutical compositions and methods for preparation and treatment |
| HUT49889A (en) * | 1988-03-31 | 1989-11-28 | Hoffmann La Roche | Process for producing acyl derivatives |
| EP0997466A1 (en) * | 1988-10-24 | 2000-05-03 | PROCTER & GAMBLE PHARMACEUTICALS, INC. | Novel antimicrobial lactam-quinolones |
| SG54293A1 (en) * | 1988-10-24 | 1998-11-16 | Procter & Gamble Pharma | Novel antimicrobial fluoroquinolonyl cephems |
| EP0366641B1 (en) * | 1988-10-24 | 2000-07-05 | Norwich Eaton Pharmaceuticals, Inc. | Novel antimicrobial quinolonyl lactam esters |
| CA2001203C (en) * | 1988-10-24 | 2001-02-13 | Thomas P. Demuth, Jr. | Novel antimicrobial dithiocarbamoyl quinolones |
| EP0366193A3 (en) * | 1988-10-24 | 1992-01-08 | Norwich Eaton Pharmaceuticals, Inc. | Novel antimicrobial quinolonyl lactams |
| US5328908A (en) * | 1988-10-24 | 1994-07-12 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolone thioureas |
| AU633867B2 (en) * | 1989-02-02 | 1993-02-11 | Eli Lilly And Company | Delivery of cytotoxic agents |
| GB8907617D0 (en) * | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| DE69132256T2 (en) * | 1990-04-18 | 2001-01-25 | Procter & Gamble Pharmaceuticals, Inc. | ANTIMICROBIAL CHINOLONYL LACTAME |
| US5066800A (en) * | 1990-04-27 | 1991-11-19 | Hoffmann-La Roche Inc. | Qunoline intermediates useful therein for synthesizing antibacterial compounds |
| US5244892A (en) * | 1990-10-16 | 1993-09-14 | Kyorin Pharmaceutical Co., Ltd. | Cephem compounds, and antibacterial agents |
| GB9216759D0 (en) * | 1992-08-07 | 1992-09-23 | Finpael Spa | Process for the production of 7-amino thiazolyl cephalosporins |
| DE4234330A1 (en) * | 1992-10-12 | 1994-04-14 | Bayer Ag | Quinolonecarboxylic acids |
| WO1995023153A1 (en) * | 1994-02-25 | 1995-08-31 | Laboratorios Aranda, S.A. De C.V. | Quinolonylcarboxamidocephalosporin derivatives and pharmaceutical compositions containing them |
| MX9505113A (en) * | 1995-12-07 | 1997-06-28 | Aranda Lab Sa De Cv | Cephalosporine-fluoroquinolonates derivatives and pharmaceutical compositions containing them. |
| US10071103B2 (en) | 2014-01-29 | 2018-09-11 | Vyome Biosciennces Pvt. Ltd. | Treatments for resistant acne |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3971778A (en) | 1972-05-12 | 1976-07-27 | Glaxo Laboratories Limited | Cephalosporins having (α-etherified oximino)acylamido groups at the 7-position |
| HU168497B (en) * | 1972-12-18 | 1976-05-28 | ||
| US4173199A (en) | 1974-12-02 | 1979-11-06 | Codama Holding S.A. | Apparatus for reinforcing a fabric by applying a fluid reinforcing material thereto |
| DE2760123C2 (en) | 1976-01-23 | 1986-04-30 | Roussel-Uclaf, Paris | 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporanic acids, their preparation and pharmaceutical compositions containing them |
| DE2716677C2 (en) | 1977-04-15 | 1985-10-10 | Hoechst Ag, 6230 Frankfurt | Cephem derivatives and processes for their preparation |
| JPS5854157B2 (en) | 1977-06-10 | 1983-12-02 | 山之内製薬株式会社 | New derivatives of cephalosporin compounds and their production method |
| JPS5630964A (en) * | 1979-08-22 | 1981-03-28 | Kyorin Pharmaceut Co Ltd | Novel substituted quinolinecarboxylic acid and its preparation |
| US4266049A (en) | 1980-02-20 | 1981-05-05 | Eli Lilly And Company | Process for 3-iodomethyl cephalosporins |
| FR2501209B1 (en) * | 1981-03-03 | 1986-07-04 | Sanofi Sa | NOVEL CEPHALOSPORIN DERIVATIVES AND ANTIBIOTIC DRUGS CONTAINING THE SAME |
| SE440354B (en) * | 1981-02-19 | 1985-07-29 | Kyorin Seiyaku Kk | quinolinecarboxylic |
| FR2570702B1 (en) * | 1984-09-27 | 1987-01-09 | Sanofi Sa | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR OBTAINING THEM AND THEIR APPLICATION AS ANTIBIOTICS |
| CA1277977C (en) * | 1985-01-21 | 1990-12-18 | Shigeo Shimizu | Beta-lactam antibiotics |
| NZ227470A (en) * | 1987-12-28 | 1991-06-25 | Hoffmann La Roche | Acyl derivatives of substituted cephem compounds; pharmaceutical compositions and methods for preparation and treatment |
-
1987
- 1987-06-29 ZA ZA874696A patent/ZA874696B/en unknown
- 1987-07-01 HU HU872981A patent/HU200185B/en not_active IP Right Cessation
- 1987-07-01 AU AU75009/87A patent/AU603364B2/en not_active Ceased
- 1987-07-01 CS CS874967A patent/CS270227B2/en unknown
- 1987-07-01 PH PH35483A patent/PH23940A/en unknown
- 1987-07-01 IL IL83046A patent/IL83046A/en not_active IP Right Cessation
- 1987-07-01 NZ NZ220914A patent/NZ220914A/en unknown
- 1987-07-02 NO NO872770A patent/NO168890C/en unknown
- 1987-07-02 CN CN87105204A patent/CN1021226C/en not_active Expired - Fee Related
- 1987-07-02 DK DK340387A patent/DK340387A/en not_active Application Discontinuation
- 1987-07-02 KR KR1019870007017A patent/KR880001675A/en not_active Ceased
- 1987-07-02 JP JP62166231A patent/JPH0730083B2/en not_active Expired - Lifetime
- 1987-07-02 IE IE176587A patent/IE61434B1/en not_active IP Right Cessation
- 1987-07-02 MC MC871895A patent/MC1833A1/en unknown
- 1987-07-02 MX MX718987A patent/MX7189A/en unknown
- 1987-07-03 ES ES87109613T patent/ES2060583T3/en not_active Expired - Lifetime
- 1987-07-03 PT PT85246A patent/PT85246B/en not_active IP Right Cessation
- 1987-07-03 ZW ZW124/87A patent/ZW12787A1/en unknown
- 1987-07-03 DE DE87109613T patent/DE3788306D1/en not_active Expired - Fee Related
- 1987-07-03 AT AT87109613T patent/ATE97901T1/en not_active IP Right Cessation
- 1987-07-03 FI FI872951A patent/FI88392C/en not_active IP Right Cessation
- 1987-07-03 EP EP87109613A patent/EP0251330B1/en not_active Expired - Lifetime
- 1987-10-08 AT AT2645/87A patent/AT391137B/en not_active IP Right Cessation
-
1991
- 1991-12-20 CS CS913950A patent/CS395091A3/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK340387D0 (en) | acyl derivatives | |
| DK345989D0 (en) | quinoline | |
| DE68919273D1 (en) | Cephalosporins, processes for their preparation and pharmaceutical preparations. | |
| DE69103490D1 (en) | Cephalosporin derivatives with position 3 a thioalkylthio group. | |
| NO175533C (en) | Preparation of morpholinyl derivatives of doxorubicin | |
| SE8802412D0 (en) | THIOUREA DERIVATIVES | |
| DK37691A (en) | SUBSTITUTED BETA DICETONES, PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS AND USE THEREOF | |
| DE69213656D1 (en) | 1-alkyl-2-acyl-1,2-disulfonylhydrazine with antineoplastic activity | |
| AU583161B2 (en) | Substituted 5-amino-1-aryl-pyrazoles | |
| AU597923B2 (en) | 5-aminoalkyl-beta-carboline derivatives, their production and their use as drugs | |
| DK32287A (en) | 3-ACYLAMINOMETHYL-IMIDAZO (1,2-A) PYRIDINE DERIVATIVES, PROCEDURES FOR PREPARING IT, AND MEDICINAL CONTAINING SUCH DERIVATIVES | |
| AU576412B2 (en) | Furazan derivatives | |
| DK656889A (en) | AZABICYCLIC DERIVATIVES | |
| DE3673057D1 (en) | 6- (1-ACYL-1-HYDROXYMETHYL) -PENICILLANSAEUR DERIVATIVES. | |
| ES2101269T3 (en) | NEW DERIVATIVES OF 1-FENYL-BICYCLE- (2.2.2) -OCTANE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |